Paper Details

  1. Home
  2. Paper Details

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.

Author: De MuynckBenoit, De SimoniStéphanie, FolschweillerNicolas, FrielDamien, HezarehMarjan, LeeBee Wah, LeungTing Fan, LimFong Seng, LiuAnthony Pak-Yin, OhHelen May Lin, RomboLars, RouzierRoman, StruyfFrank, SuryakiranPemmaraju, TanNgiap Chuan, ThollotFranck, ThomasFlorence

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study comparing the immunogenicity and safety of HPV vaccines found that 2 doses of the HPV-16/18 AS04-adjuvanted vaccine elicited superior HPV-16/18 antibody responses compared with 2 or 3 doses of the HPV-6/11/16/18 vaccine in girls aged 9-14 years.
Paper Details　
Original Abstract of the Article :
This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of 2 doses of the HPV-16/18 AS04-adjuvanted vaccine (HPV-16/18(2D)) vs. 2 or 3 doses of the HPV-6/11/16/18 vaccine (HPV-6/11/16/18(2D) and HPV-6/11/16/18(3D)) in healthy girls aged 9-14 y. Girls were ra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514190/

データ提供：米国国立医学図書館（NLM）

The HPV Vaccine: A Shield Against the Sands of Time

The realm of immunology is constantly evolving, seeking new ways to protect us from the ravages of disease. This research delves into the comparative efficacy and safety of different HPV vaccines, akin to comparing different oases in a vast desert. It explores the immunogenicity and safety of a two-dose HPV-16/18 AS04-adjuvanted vaccine compared to two or three doses of the HPV-6/11/16/18 vaccine in young girls aged 9-14. The authors employed a randomized trial design, like carefully selecting the path through a desert, to ensure a balanced comparison.

A Superior Shield: Two Doses for Better Protection

The results suggest that the two-dose HPV-16/18 AS04-adjuvanted vaccine elicits superior antibody responses compared to the two or three-dose HPV-6/11/16/18 vaccine. This is like finding an oasis that offers a more plentiful supply of water, providing greater protection against the challenges of the desert. The authors observed this superiority both in the short-term (month 7) and long-term (month 12) follow-up periods.

Strengthening Our Defenses: A Vital Step Towards a Healthier Future

These findings reinforce the importance of vaccination in protecting young women against HPV-related cancers. It's like building a strong caravan, well-equipped to withstand the harsh realities of the desert journey. By providing robust protection, we can reduce the risk of these cancers, paving the way for a healthier future.

Dr.Camel's Conclusion

This research sheds light on the importance of choosing the right HPV vaccine to maximize protection. Like choosing the best oasis for a caravan, selecting the most effective vaccine can lead to a safer and healthier journey through life. The two-dose HPV-16/18 AS04-adjuvanted vaccine appears to be a promising option for girls aged 9-14.

Date :
  1. Date Completed 2016-05-09
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26062002

DOI: Digital Object Identifier

PMC4514190

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.